Waverley Pharma Inc.
WAVE.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 46.14% | 76.71% | 20.60% | -28.64% | 80.01% |
| Total Depreciation and Amortization | 0.00% | 520.83% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -91.51% | 99.06% | -2.74% | -5.60% | -96.66% |
| Change in Net Operating Assets | -35.42% | -137.11% | 346.40% | -47.32% | 169.78% |
| Cash from Operations | -66.81% | -296.79% | 118.75% | -119.83% | 76.54% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -152,800.00% | 100.02% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 31,500.00% | 100.02% | -- | -- | -- |
| Total Debt Issued | -65.64% | -87.37% | 197.97% | 122.08% | -77.54% |
| Total Debt Repaid | 13.13% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -72.56% | -88.98% | 198.97% | 118.69% | -77.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,579.17% | -101.78% | 16,775.00% | 0.00% | -94.94% |